Telehealth Reality Check: Who’s Really Going to “Win” the Race to Virtual Care Market Leadership?

By JESSICA DaMASSA, WTF HEALTH

It’s the telehealth market reality check you’ve been waiting for! “Rouge” digital health consultant Dr. Lyle Berkowitz unpacks the numbers and the market potential for virtual care from the unique vantage point of a primary-care-physician-turned-health-tech-entrepreneur with nothing to lose. Having been 1) a clinician, 2) the Director of Innovation at Northwestern Medicine, 3) the founder of a health tech startup (Health Finch) that successfully exited to Health Catalyst, and 4) the former Chief Medical Officer at one of telemedicine’s biggest players, MDLive, few can boast such a wide-reaching, deep understanding of the inner workings of both the innovation and incumbent sides of the virtual care market — AND have a willingness to talk about it all with complete candor!

This is an analyst’s perspective on the telehealth market — with a twist of insider expertise — so expect to hear some good rationale behind predictions about how much care will remain virtual once hospitals and doctor’s offices return to normal, how “real” health system enthusiasm is for building out telehealth capacity to execute on the “digital front door” idea, and whether or not all these well-funded telehealth startups will have what it takes to win market share from traditional care providers.

BONUS on Primary Care: Is this the area of medicine that’s going to be the “battleground” where digital health and virtual care companies will be going head-to-head with incumbents for market share? Lyle says 50-plus percent of primary care “can and should be automated, delegated, virtualized, etc.” and boldly predicts that in 10-20 years we won’t even have primary care physicians anymore. Tune in to find out why starting at the 8:00 minute mark, where we shout out Crossover Health, Oak Street Health, Iora Health, and more.

Telehealth die-hards, don’t think for a second I’d miss this chance to also get some input on Teladoc-Livongo, Amwell, Doctor On Demand, SOC Telemed, the impending IPOs there, digital first health plans, virtual primary care, health systems (who Lyle hopes “don’t shoot themselves in the foot” with their opportunity to jump into the space) and, ultimately, who’s really going to ”WIN” in virtual care moving forward. For this, jump in at 17:00 minutes and hold on!

from The Health Care Blog https://ift.tt/2SpJ3Rr

Obstacles to Value-Based Care Can Be Overcome

By KEN TERRY

(This is the seventh in a series of excerpts from Terry’s new book, Physician-Led Healthcare Reform: a New Approach to Medicare for All, published by the American Association for Physician Leadership.)

Even in a healthcare system dedicated to value-based care, there would be a few major barriers to the kinds of waste reduction described in this book. First, there’s the ethical challenge: Physicians might be tempted to skimp on care when they have financial incentives to cut costs. Second, there’s a practical obstacle: Clinical guidelines are not infallible, and large parts of medicine have never been subjected to rigorous trials. Third, because of the many gaps in clinical knowledge, it can be difficult for physicians to distinguish between beneficial and non-beneficial care before they provide it.

Regarding the ethical dimension, insurance companies often are criticized when they deny coverage for what doctors and patients view as financial reasons. Physicians encounter this every day when they request prior authorization for a test, a drug, or a procedure that they believe could benefit their patient. But in groups that take financial risk, physicians themselves have incentives to limit the amount and types of care to what they think is necessary. In other words, they must balance their duty to the patient against their role as stewards of scarce healthcare resources.

On the other hand, fee-for-service payment motivates physicians to do more for patients, regardless of whether it’s necessary or not. In some cases, doctors may order tests or do procedures of questionable value to protect themselves against malpractice suits; but studies of defensive medicine have shown that it actually raises health costs by a fairly small percentage. More often, physicians overtreat patients because of individual practice patterns or because they practice in areas where that’s the standard of care. As long as doctors believe there’s a chance that the patient will benefit from low-value care, they can justify their decision to provide that care.

The Institute of Medicine (IOM), in its book Crossing the Quality Chasm, neatly encapsulated the contrasting incentives of fee for service and prepaid or budgeted care.

Under fee for service, there is a potential for overuse of services by increasing the intensity of care and treating more patients. Also, since the method is based on individual units of care or service, it can be difficult to coordinate payment across the many members of a care team….

The advantages of a budgeted approach are that it provides an incentive to control costs and produce care efficiently, and can encourage innovation in cost-reducing technologies, use of lower-cost settings of care, and investment in health promotion and disease prevention….Disadvantages include the potential for risk selection to avoid patients who might be high-cost users of care, and the potential to provide insufficient or reduced quality of services to minimize costs and stay within budget.

[Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001:186-188]

Risk adjustment can eliminate the temptation to shun higher-risk patients, and the use of data analytics—which hardly existed when the IOM book was written—can help at-risk groups stay within their budgets without skimping on care. To be successful, the primary care groups in the physician-led reform model would have to incentivize their doctors to provide high-quality care, first and foremost. Kaiser Permanente’s physicians, for example, receive salaries and are not directly incentivized to cut costs. Instead, the group culture has internalized efficiency.

“Separating clinical decision making from actual payment is what drives quality,” Richard Isaacs, CEO and executive director of the Permanente Medical Group, told me. “That’s patient-centered care, where you’re doing what’s best for the patient.”

Wasteful vs. Beneficial Care

One reason waste is hard to eliminate is that it’s often difficult to detect. In the book The Hippocratic Myth, M. Gregg Bloche, MD, a professor of law at Georgetown University, says that while up to 30% of healthcare might be wasted, “we don’t know, until after the fact, which care is pointless under what conditions.”

While one might expect that experienced physicians know how to distinguish between beneficial and non-beneficial care, that assumption presupposes that they’ve been able to keep up with the latest studies, Bloche said in an interview. Moreover, he noted, “the majority of clinical scenarios are not situations that have been studied and analyzed in a randomized controlled fashion. Even when there have been randomized controlled trials, the inclusion criteria required to make such studies effective statistically are pretty narrow. That’s great from the perspective of doing a good study. But the more you narrow the inclusion criteria, the less relevant your study is to patients in the wild.”

Nevertheless, there are many common scenarios where doctors know perfectly well whether care is being wasted. That’s why three of four U.S. physicians said in a 2017 survey that the frequency with which doctors order unnecessary medical tests and procedures is a serious problem for the health system.

Meanwhile, busy doctors can’t keep up with the flood of new evidence, and many of them prescribe drugs pushed by sales reps brandishing biased studies. Even when physicians follow guidelines based on rigorous trials, some of their patients don’t respond well to what those guidelines recommend. Hence, if a group requires its doctors to follow agreed-upon protocols, they must be given the freedom to deviate from them.

Despite all these caveats, however, it’s physicians who provide, order, or supervise most of the care that patients receive. Consequently, they are the only healthcare players who can significantly reduce the waste in the system. But they’re not going to do it under external pressure. Rather than being buffaloed by insurance companies, as many doctors are today, they should take the buffalo by the horns and manage care themselves. Because physicians have a trust relationship with their patients, they also have a unique ability to persuade patients that more care isn’t always better care. If our country is going to make a real effort to cut waste enough to make healthcare affordable, physicians are the ones to do it.

Ken Terry is a journalist and author who has covered health care for more than 25 years. He tweets @kenjterry.

from The Health Care Blog https://ift.tt/2EKX7S4

Health in 2 Point 00, Episode 154 | Health Tech Rounds, Socialized Medicine, & the ACA

On Episode 154 of Health in 2 Point 00, follow @barkyboy (a dog wearing a Health in 2 Point 00 shirt!) on Twitter! Jess also asks me about Papa getting $18M in a Series B for their matching platform for college students, Optimize.health raising $15.6M in a Series A for their RPM platform, Joint Academy raising $23M for their physical therapy platform, and Maple Corp raising $75M for their Canadian telehealth platform in socialized medicine. Also, Matthew talks about his new piece on THCB where he wrote about what Biden should say to the Supreme Court Justices on the ACA. Matthew Holt

Subscribe to Health in 2 Point 00’s Channel

Follow @boltyboy & @jessdamassa on Twitter

Subscribe to our channel and tweet us your questions using the hashtag #healthin2point00!

from The Health Care Blog https://ift.tt/346uo2Y

Trying to Make AI Less Squirrelly

By KIM BELLARD

You may have missed it, but the Association for the Advancement of Artificial Intelligence (AAAI) just announced its first annual Squirrel AI award winner: Regina Barzilay, a professor at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL).   In fact, if you’re like me, you may have missed that there was a Squirrel AI award.  But there is, and it’s kind of a big deal, especially for healthcare – as Professor Barzilay’s work illustrates. 

The Squirrel AI Award for Artificial Intelligence for the Benefit of Humanity (Squirrel AI is a Chinese-based AI-powered “adaptive education provider”) “recognizes positive impacts of artificial intelligence to protect, enhance, and improve human life in meaningful ways with long-lived effects.”  The award carries a prize of $1,000,000, which is about the same as a Nobel Prize

Yolanda Gil, a past president of AAAI, explained the rationale for the new award: “What we wanted to do with the award is to put out to the public that if we treat AI with fear, then we may not pursue the benefits that AI is having for people.”

Dr. Barzilay has impressive credentials, including a MacArthur Fellowship.   Her expertise is in natural language processing (NLP) and machine learning, and she focused her interests on healthcare following a breast cancer diagnosis.  “It was the end of 2014, January 2015, I just came back with a totally new vision about the goals of my research and technology development,” she told The Wall Street Journal. “And from there, I was trying to do something tangible, to change the diagnostics and treatment of breast cancer.”

Since then, Dr. Barzilay has been busy.  She’s helped apply machine learning in drug development, and has worked with Massachusetts General Hospital to use A.I. to identify breast cancer at very early stages.  Their new model identifies risk better than the widely used Tyrer-Cuzick risk evaluation model, especially for African-American women. 

As she told Will Douglas Heaven in an interview for MIT Technology Review:  “It’s not some kind of miracle—cancer doesn’t grow from yesterday to today. It’s a pretty long process. There are signs in the tissue, but the human eye has limited ability to detect what may be very small patterns.”

This raises one of the big problems with AI; we may not always understand why AI made the decisions it did.  Dr. Barzilay observed:

But if you ask a machine, as we increasingly are, to do things that a human can’t, what exactly is the machine going to show you? It’s like a dog, which can smell much better than us, explaining how it can smell something. We just don’t have that capacity.

She firmly believes, though, that we can’t wait for “the perfect AI,” one we fully understand and that will always be right; we just have to figure out “how to use its strengths and avoid its weaknesses.”   As she told Stat News, we have a long way to go: “We have a humongous body of work in AI in health, and very little of it is actually translated into clinics and benefits patients.”

Dr. Barzilay pointed out: “Right now AI is flourishing in places where the cost of failure is very low…But that’s not going to work for a doctor… We need to give doctors reasons to trust AI. The FDA is looking at this problem, but I think it’s very far from solved in the US, or anywhere else in the world.” 

A concern is what happens when A.I. is wrong.  It might predict the wrong thing, fail to identify the right thing, or ignore issues it should have noticed.  In other words, the kinds of things that happen every day in healthcare already.  With people, we can fire them, sue them, even take away their license.  With A.I., what we do to whom/what is not at all obvious.

“This is a big mess,” Patrick Lin, director of Ethics and Emerging Sciences Group at California Polytechnic State University, told Quartz. “It’s not clear who would be responsible because the details of why an error or accident happens matters.” 

Wendall Wallace, of Yale University’s Interdisciplinary Center for Bioethics, added: “If the system fails to perform as designed or does something idiosyncratic, that probably goes back to the corporation that marketed the device.  If it hasn’t failed, if it’s being misused in the hospital context, liability would fall on who authorized that usage.”

“If it’s unclear who’s responsible, that creates a gap, it could be no one is responsible,” Dr. Lin said. “If that’s the case, there’s no incentive to fix the problem.”  Oh, great, just what healthcare needs: more unaccountable entities.

To really make AI succeed in healthcare, we’re going to have to make radical changes in how we view data, and in how we approach mistakes.

AI needs as much of data as it can get.  It needs it from diverse sources and on diverse populations.  All of those are problematic in our siloed, proprietary, one-step-from-handwritten data systems.  Dr. Barzilay nailed it: “I couldn’t imagine any other field where people voluntarily throw away the data that’s available. But that’s what was going on in medicine.” 

Despite our vaunted scientific approach to medicine, the fact is that we don’t really know what happens to most people most of the time, and do a poor job of counting even basic healthcare system interactions, like numbers of procedures, adverse outcomes, even how much things cost.  As bad as we are at tracking episodic care, we’re even worse at tracking care — much less health — over time and across different healthcare encounters. 

Once AI has data, it is going to start identifying patterns, some of which we know, some of which we should have known, and some of which we wouldn’t have ever guessed.  We’re going to find that we’ve been doing some things wrong, and that we could do many things better.  That’s going to cause some second-guessing and finger-pointing, both of which are unproductive.

Our healthcare system tends to have its head in the sand about identifying errors/mistakes, for fears about malpractice suits (justified or not).  Whatever tracking does happen is rarely disclosed to the public.  That’s a 20th century attitude that needed to be updated in an AI age; we should be thinking less about a malpractice model and more about a continuous quality improvement model.

“The first thing that’s important to realise is that AI isn’t magic,” David Champeaux of Cherish Health said recently.  It’s not, but neither is what we already do in healthcare.  We need to figure out how to demystify them. 

Kim is a former emarketing exec at a major Blues plan, editor of the late & lamented Tincture.io, and now regular THCB contributor.

from The Health Care Blog https://ift.tt/3n4rdRK

Talking Politics in the Exam Room: A Physician’s Obligation to Discuss the Political Ramifications of Science with Patients

By HAYWARD ZWERLING

I walked into my exam room to see a patient I first met two decades ago. On presentation, his co-morbidities included poorly controlled DM-1, hypertension, hyperlipidemia, and a substance abuse disorder. Over the years our healthcare system has served him well as he has remained free of diabetic complications and now leads a productive life. Watching this transformation has been both professionally rewarding, personally enjoyable, and I look forward to our periodic interactions.

At this visit, he was sporting a MAGA hat. I was confused. How can my patient, who has so clearly benefited from America’s healthcare system, support a politician who has tried to abolish the Affordable Care Act, used the bully pulpit to undermine America’s public health experts, refused to implement healthcare policies which would mitigate COVID-19’s morbidity and mortality, and who minimizes the severity of the coronavirus pandemic every day. Why does he support a politician whose healthcare policies are an immediate threat to his health and longevity?

My brain says, “You are the physician this patient trusts to take care of his medical problems. You must teach him that COVID-19 is a serious risk to his health and explain how the President’s public health policies threatens his health. You must engage in a political conversation.”

It is currently taboo for physicians to discuss politics in the exam room, especially when political opinions are discordant as it risks creating a rift in the patient-physician relationship. Reflexly, I answer myself “Do not engage in a political discussion, you need to deal with his immediate health issues.”
During the visit, we reviewed his medicines and test results and agreed on a treatment plan. At the end of the visit, I told him that it is in his best health interest to wear a mask, socially distant, wash his hands frequently, and defer visiting his favorite bar and gym. I consciously decided not to address his support for the President. 

Back in my office, I reviewed the encounter and immediately had misgivings about my decision to avoid discussing the health ramifications of his political proclivities. I knew he was mistakenly informed about the science of COVID-19, as his primary source of information was Fox News and his peers. I was concerned that this misunderstanding led him to support a politician whose public health policies will adversely impact his health.

Every day physicians teach their patients the scientific truths they must understand to enable them to make informed healthcare decisions. Is it not also a physician’s responsibility to teach their patients the science underlying relevant public health policy and explain that there is a linear connection between political choices, public health policies, and their health and longevity? Would not a more comprehensive understanding of this relationship enable our patients to make more informed political decisions, including the option to choose political leaders who will implement better healthcare policies?

While politics has become hyperpolarized, most patients still believe their physicians tell the truth about science and medicine; thus physicians are in a unique position to educate their patients about the ramifications of science.

By selecting me as his physician, he was implicitly telling me that he had confidence in my judgment. In return, I should have emphasized that the coronavirus is an immediate risk to his health, I should have explained how COVID-19 spreads and how he can reduce his risk. I probably should have breached the “no politics in the exam room” taboo and told him that the President’s refusal to implement public health measures recommended by every public health expert has resulted in the needless death of tens of thousands of Americans and is part of the reason that 1,000 Americans die from COVID-19 every day. I should have explicitly connected the dots and stated that the President’s COVID-19 public health policy is an immediate threat to his health.

The medical profession now understands that social determinants of health are probably the most important driver of a patient’s overall health and these determinants are largely the result of political decisions. Clearly, we have a professional responsibility to teach our patients the science underlying their health issues. Don’t we also have a professional obligation to ensure that our patients understand the health ramifications of their political choices? If that is the case, do we not have a professional obligation to initiate a conversation about the political issues which impact our patients’ health?

If we fail to breach the taboo of “talking politics” in the exam room, are we not shirking our professional responsibilities to our patients and society?

Hayward Zwerling is an endocrinologist with an interest in health information technology, health care policy, woodworking, and politics.

from The Health Care Blog https://ift.tt/2SjtSsZ

Biden’s Nov 9th speech: “Don’t you force me to pass Medicare 4 All”

By MATTHEW HOLT

The new Supreme Court, in all likelihood including just nominated Justice Amy Coney Barrett, will be hearing the California v Texas suit against the ACA on November 10th, seven days after the election. The lower courts have already ruled the ACA unconstitutional. Some hopeful moderates among my Democratic friends seem to believe that the justices will show cool heads, and not throw out the ACA. But it’s worth remembering that in the NFIB vs. Sebelius decision which confirmed the legitimacy of most of the ACA back in 2011 all the conservative justices with the exception of John Roberts voted to overturn the whole thing. With Ginsburg being replaced by Barrett there’s no reason to suppose that she won’t join Thomas, Alito, Kavanagh & Gorsuch and that Robert’s vote won’t be enough to stop them this time. The betting odds must be that the whole of the ACA will be overturned.

There is nothing the Democrats can realistically do to prevent Barret filling RBG’s seat on the court, but assuming Biden wins and the Democrats take back the Senate, the incoming Administration can give the Supremes something to think about regarding the ACA. I would not suggest this level of confrontation before the election but, if Biden wins, the gloves must come off.

Assuming he wins and that the Dems win the Senate, this is the speech Biden should give on November 9th. (The TL:DR spoiler is, “Keep the ACA or I’ll extend Medicare to all ages”)

“I’m directing this speech to an extremely select number of people, just the Supreme Court Justices appointed by Republican Presidents. It is obviously no secret that we have political differences on many issues and we find ourselves in the strange situation in which I am the incoming President with an incoming Democratic Senate majority and yet you are considering overturning the signature bill of the administration in which I was Vice-President. You may recall that at the time of its signing I told President Obama that it was a “big f****** deal”  and, although many of my colleagues in the more progressive wing of the Democratic Party have criticized the ACA since its passage, it turns out that I was right. 

I am not referring here to the apoplexy that the ACA created amongst the Republican Party including not only the current and outgoing President but also almost all Republican members of Congress between 2010 and 2018. Instead I’m referring to the ACA’s impact on the nation and its health care system. 

Since 2010 there have been many changes to the way our nation’s health care system operates; almost all of them have their roots in the ACA. 

First, the ACA gave access to health insurance coverage to many people who had great trouble getting it before. That includes young people moving between their parent’s home, college and getting into the workforce; small business owners; freelance workers; the unemployed; people with low incomes; and people with underlying “pre-existing” health conditions. I remind you that due both to the pandemic and changes in our economy, there are many, many more of these people now than there were in 2009. 

Before the ACA these people were either not well served by the private health insurance industry or literally were unable to buy coverage at all. This not only caused extreme personal and financial suffering and in some cases death to the people affected, but also impacted the economy. It restrained innovation and entrepreneurship, and it meant that the participants in the health care system–including very many well meaning clinicians and provider organizations–had to play very inefficient games in order to try to provide those people with much-needed care, which drove up the cost of care to everyone else. Warren Buffet calls that the tapeworm in the US economy.

The ACA changed this in two main ways.

First it created a system of standardized insurance benefits and mandated insurers to provide those benefits to anybody regardless of health status. It also directly subsidized the cost of insurance for people of low to moderate-incomes. Given that median household income is around $63,000 in the US and the current cost of family insurance is around $28,000, these subsidies are essential. Otherwise people who do not have employment-based insurance would not be able to purchase coverage.

Second, the ACA expanded Medicaid coverage for the poor, creating a standardized set of benefits for those earning up to 133% of poverty. Sadly, the conservative majority on the court, joined (in my view to their everlasting shame) by Justices Breyer and Kagan, decided that the federal government did not have the right to force states to expand Medicaid even though the federal government paid 100% of the cost. It turned out that many states with Republican governors chose not to expand Medicaid, even though this meant that many rural hospitals in their states were forced to close. Numerous studies have shown that Medicaid expansion has improved the financial and emotional health of the poor, and other work has shown that the current Administration’s policy of allowing states to restrict access to Medicaid, by using such tricks as work requirements, have been cruel and counterproductive–and that they have not reduced health care costs or increased employment. States that have not expanded Medicaid have left their most vulnerable and poor populations an extremely difficult state. For example in Texas a single parent with two  children is only eligible for Medicaid if the children are on Medicaid and total household income doesn’t exceed $230 a month, which would barely cover your clerks’ daily lunch bill. Some estimates suggest that nearly three-quarters of a million people in Texas are in the coverage gap between Medicaid and qualifying for the ACA.

However, the ACA was not just about expanding insurance for those who had trouble getting it before. It also closed several loopholes that had confronted many other people who needed to use the health care system. This included closing the donut hole in the drug coverage for seniors provided by the Medicare Modernization Act in 2003. It also did away with maximum coverage benefits which severely compromised the care received by extremely sick people–often children or those with very rare diseases. And, in a great benefit to many, many young Americans from middle class and even wealthy families, the ACA allowed parents to keep their children on their insurance up until the age of 26, when they were usually established in the workforce.

Many of you on the Supreme Court believe that private delivery of insurance and health care services are superior to those delivered by the government. For you the ACA should indeed have been a very welcome piece of legislation. All of the new enrollment coming through the ACA exchanges went through private health insurance companies, and the vast majority of Medicaid expansion is also managed by private health insurers. While federal tax dollars are subsidizing this coverage expansion, it’s worth pointing out that a IRS decision in 1954 confirmed the tax-free status of private health insurance premiums paid by employers which translates to an annual subsidy to private employers that exceeds the cost of the premium subsidies in the ACA. On the night that the ACA was passed a Canadian journalist reported that America had just seen the largest expansion of private health care coverage ever–and he was right.

This coverage expansion was by no means all that the ACA did. It was also the legal and regulatory basis for a substantial modernization of the nation’s health care system. Of course since the 1930s, US health care has largely been based on a fee-for-service payment approach, acknowledged by experts to be both inefficient and inflationary. The ACA created the Center for Medicare and Medicaid Innovation which has been at the forefront of creating programs that encourage improved care at a lower cost by, for instance, bundling payments for joint surgery, cancer and other care. It also created the system of accountable care organizations which encourages doctors and hospitals to work together to more efficiently and effectively manage the health of large populations of Medicare recipients. And while the ACA did not create the Medicare Advantage program, it put in place an environment in which private health insurance companies were able to use government funding within the Medicare program to deliver innovative programs that are improving the quality of care received by our seniors. 

In addition, since the passage of the ACA, and assisted by it and the HITECH Act passed in 2009, there has been a considerable boom in the development of new types of health care technologies, particularly digital technologies. These show amazing promise for delivering 24/7 care to many vulnerable populations. The significant spread of telehealth and remote patient monitoring during the current COVID-19 pandemic was only possible because of the innovation of numerous private companies. They developed those technologies in large part in response to incentives created by the ACA.

Finally, although the cost of health care in the United States is still significantly higher than it is in other countries, since the passage of the Affordable Care Act the rate of increase of health care cost has slowed and up until this year the health care system was barely growing as a share of the overall economy for the first time ever (other than a brief blip in the mid 1990s).

This is just a brief overview of the impact of the Affordable Care Act. It has directly meant access to health care coverage for around 20 to 30 million people and, as health futurist Ian Morrison points out, has tentacles impacting every single part of the health care system. This was not the case when four conservative justices including two currently on the bench (Alito & Thomas) voted to throw out the ACA in 2012. And it has not escaped my attention that the two justices who have replaced Scalia and Kennedy appear to have similar or perhaps even more conservative viewpoints.

If following the arguments you will hear this week, the Supreme Court decides to uphold the lower court hearing and abolish the entire ACA on what is pretty much a technicality, the consequences will be dramatic. And they will be very bad.  

Tens of millions of people will lose their health insurance. Of course they will still require care. The cost of delivering that care will fall upon the nation’s health care providers, and eventually on the taxpayer. That cost will be distributed in an unplanned and chaotic manner –resulting in much actual and financial pain.

In addition, virtually every current organization funding, delivering or involved in care delivery will have to completely reformat the business operations it has spent the last decade putting in place. American health care will be thrown into chaos and the cost in both dollars and human suffering will be extreme. 

Given the extreme impact of throwing out the ACA,  I will appeal to all the justices to maintain the ACA in place.

Unlike the outgoing president, I respect the institutions and separation of powers inherent in the constitution of our nation. But given that I and my colleagues in the Senate have just been elected by a significant majority of Americans, and also given that none of the conservative justices on the court were appointed by a President who won the majority of the vote of his fellow citizens, I would recommend that the court consider its actions very carefully. Unlike some in my party, I am not advocating significant constitutional changes such as appointing more justices, but the more the court bends against the arc of history, the more likely it is that such actions may be taken in the future.

However, in regards to the nation’s health care system I am hereby telling you exactly what I will do–should the court return a verdict overturning the ACA.

You are well aware that in the Democratic primary campaign, which was largely settled before the covid-19 pandemic had its full effect, my opponent Senator Sanders was campaigning to create Medicare for All. While I was and am opposed to this policy, it is clear that a significant majority of Democrats and in some polling a majority of Americans were in favor of expanding Medicare For All even before the full effect of the pandemic was realized. 

The world of course is radically different now compared to how things were even at the start of 2020. Not only has our health care system had to deal with the onslaught of the pandemic, but the recession that it caused has placed many more millions of Americans out of work, and some 5 million of those have already lost their health insurance. I pledged in the election campaign both to get the economy moving and also to support those who were victims of the recession, which includes those millions who lost their health insurance. 

In my campaign I pledged to build on the successes of the ACA. As you are well aware, two of the most significant policies I proposed were to create a public option and to reduce the eligibility age for Medicare to 60 years old. If the Supreme Court throws out the ACA, it will be by definition impossible for me to build on the ACA’s infrastructure.

But at a time of a pandemic during a recession I will not stand by and allow tens of millions of Americans to suffer. 

Instead let me tell you what I will do. 

As you know under the current rules of the Senate and from the convoluted passage of the ACA itself, it is virtually impossible to pass significant legislation without 60 votes. In the election that just happened we Democrats have retaken control of the Senate, but only with a slight majority. However, as you also know, the Senate can pass legislation impacting budgets under the process of reconciliation with a simple majority. You will recall that using reconciliation the Republican majority in the Senate tried to repeal the ACA in 2017, and were only prevented from doing so by the deciding vote of my friend the late Senator John McCain.

On the day which I hope never comes that the Supreme Court invalidates the ACA, my colleagues in the House and Senate will immediately introduce legislation amending Title 18 of the 1965 Social Security Act that created Medicare to reduce the age of eligibility not to 60 but to zero. At the same time we will amend title 19 of the 1965 Social Security Act that created Medicaid to reduce its budget to $0 other than to pay the premiums into Medicare for those known as “dual eligibles” and to pay for long term care and other services that Medicare currently doesn’t cover.

You and other conservatives might believe that we will not be able to complete this because of the Byrd Rule for reconciliation which was designed in the 1980s to ensure that reconciliation did not radically change the budget of the federal government. But the Senate Republican majority in the Congress before last essentially already violated these rules by passing a scandalously unfair and unfunded tax cut, and my colleagues in the Senate will be prepared to override the Byrd Rule. This, I point out, is significantly less controversial than overriding the filibuster or changing the number of justices on the Supreme Court.

Conservatives might also believe that Medicare expansion would significantly increase the budget of the federal government. This would be true but is ignoring two salient facts. The first is that the expansion to the federal budget would be something of the order of 2 trillion dollars a year, as the federal government already spends roughly 1.5 trillion of the 3.5 trillion the United States spends on health care. That level of expansion of government is somewhat similar to the deficit spending which just happened under the CARES act and other stimulus money spent during the current pandemic. So it’s not that large a leap for the country to make.

In addition while the expansion of Medicare under reconciliation would not directly abolish private health insurance in the manner that my colleague Senator Sanders has proposed, the fact that Medicare part A is free to Medicare recipients, and that parts B & D are very heavily subsidized, will mean that it is not only those who have lost their insurance or have trouble buying it in the individual market, or those who were previously on Medicaid, who will voluntarily enter the Medicare program. It is extremely likely that the vast majority of employers who are currently providing health insurance for their employees, which to be noted would be voluntary if there is no ACA, will cease to do that. After all their employees could now enter the Medicare program at no extra cost to them. While this will cost the government more, it will save employers and individuals an approximately equal amount and so the net effect on the economy will be limited.

Part of the reason that I am not a proponent of Medicare for all, has been that the change it would cause to employer-based health insurance, and to the finances of our nation’s health care system would be too extreme. It is worth noting that Rand  recently showed that employer-based health insurance paid hospitals and doctors at nearly 250% the rate they receive from Medicare. There will certainly be high transition costs for the health care system from this move but everyone in the health care system already understands how Medicare works. My Administration will to work with providers and care delivery organizations to make sure that they are able to fulfill their mission of providing high-quality care to Americans.

Even though I have been a political centrist my entire life and have never been a proponent of Medicare For All–despite the fact that every other industrialized nation has something pretty similar to it–if you strike down the ACA I will act immediately. I would view the suffering of Americans as being too great not to respond. With no ACA in place there is no available legislative option other than this Medicare expansion.

I am well aware of the ideology of many on the political right in the US including most of the conservative justices on the Supreme Court. I would stress that this type of radical expansion of Medicare is not what I would ordinarily want to see. But if the ACA is abolished in the middle of a pandemic and a massive depression, my first duty to the American people as their President will be to relieve the suffering of as many of them as possible.

As you consider your judgement in the California v Texas case I would ask you not to put me in the position where I would have to take such a radical step.  

But I assure you that if necessary I will have no hesitation in doing so.

Matthew Holt is the publisher of THCB. He has not written a speech for Joe Biden before but would happily lend him this one

from The Health Care Blog https://ift.tt/309PDje

Measuring the Effectiveness of Cost-of-Care Conversations

By NELLY GANESAN, JOSH SEIDMAN, MORENIKE AYOVAUGHAN, and RINA BARDIN

With support from the Robert Wood Johnson Foundation, Avalere assesses opportunities to normalize cost-of-care conversations through measurement.

Cost continues to pose a barrier to accessing healthcare for millions of Americans. Research has shown that conversations addressing costs among patients, caregivers, and the clinical team can help build a more trusted relationship between patients and clinicians.

Avalere has partnered with Robert Wood Johnson Foundation (RWJF) since 2015 to work toward normalizing cost-of-care (CoC) conversations in clinical settings, including identifying barriers and facilitators to engaging in conversations about cost. CoC conversations can be defined as discussions that address any costs patients and families might face, from out-of-pocket (OOP) to non-medical costs (e.g., transportation, childcare, lost wages). To that end, Avalere collaborated with the National Patient Advocate Foundation to explore the feasibility of patient-centered measure concepts to support quality improvement, increase satisfaction, and improve outcomes. This issue brief highlights the challenges associated with measurement in this space alongside alternative solutions to encourage CoC conversations in practice.

Avalere thoroughly evaluated clinician and patient needs and developed a set of measure concepts and improvement activities to improve the frequency and quality of CoC conversations. Based on the gaps identified, Avalere assessed the following individual concepts and improvement activities:

  • Concept 1: Discussion of a CoC with patient during a clinic visit
  • Concept 2: Assignment of a case worker to address financial concerns
  • Concept 3: Documentation of treatment plan modification based on a CoC conversation
  • Concept 4: Patient-reported assessment of a CoC conversation during a clinic visit
  • Activity 1: Use of a patient-facing tool to prepare patients for CoC conversations
  • Activity 2: Use of a discharge-planning tool to outline costs of prescriptions post-discharge

Concepts identified through this work can move the needle toward normalizing these conversations. However, more research is needed to transform them into quality measures that could be used for accountability and improvement purposes. Our findings indicate the following research opportunities for consideration:

  • Accessibility of Data: Many clinicians are doing the best they can to address cost concerns in the absence of OOP cost information. To optimize conversations, clinicians need access to more data to feel comfortable engaging in meaningful and productive CoC conversations. There are opportunities to collaborate with public and private payers to determine the operations and functionality of accessing this data in a timely manner.
  • Roles and Responsibilities: CoC conversations are a newer concept to healthcare; thus, there is no clear role within the care team as to who should lead these conversations—and the right role may depend on the type of cost concern and on who is capable of working to address the concern. Team-based care is about meeting patients where they are by aligning the appropriate clinical team member to varying patient needs during the care episode. Having the right conversation at the right time could have a significant impact on how the patient engages with the care team and their long-term outcomes.
  • Validating the Needs of Patients: Patients—particularly low-income and vulnerable patients—may feel they are subject to unintended consequences as a result of CoC conversations (this includes lack of access to treatments as a result of a patients’ financial status). A patient’s assessment of the quality of a conversation and whether they have the information they need to make a decision about their care signals the need for more patient-reported outcome measures to ensure patients’ needs are met and that they are being heard throughout their care journey.

Thoughtful, sensitive CoC conversations can facilitate a more trusted partnership between clinicians and patients and prevent missed opportunities to address cost concerns that may have not been raised otherwise. Normalizing these conversations has the potential to reduce stigma and help to reduce disparities in outcomes. This issue brief highlights specific strategies for encouraging clinicians to talk to their patients about costs of care. Future testing and validation should ensure the measures introduced in this Issue Brief are feasible in practice to facilitate integration into existing or novel payment models. In addition, CoC measure development efforts should address the varied priorities and needs of all patients, including financial issues and barriers to equitable outcomes.

Download the issue brief.

Nelly Ganesan, MPH, is a Principal at Avalere Health. Josh Seidman, PhD, is a Managing Director at Avalere Health. Morenike AyoVaughan, MPH, is a Consultant II at Avalere Health. Rina Bardin is a Senior Associate at Avalere Health.

This post originally appeared on Avalere here.

from The Health Care Blog https://ift.tt/3cuWwQZ

Health in 2 Point 00, Episode 153 | GoodRx’s massive IPO, Olive, Bright Health & more

Today on Health in 2 Point 00, Jess is in Jacksonville hanging out with Jackson the dog and trying to replace me with @barkyboy. On Episode 153, we cover the biggest IPO we’ve seen yet—GoodRx—with a valuation of $18 billion, which is more than Teladoc, Livongo, and even Cardinal Health. In other news, Olive gets $106 million bringing their total to $220 million; Olive is a back office automation system using AI for hospitals and this round is practically financed by royalty. Bright Health gets $500 million for their health plan; they’ve raised about $1.5 billion and are planning to expand into more markets. Finally Osso VR raised $14 million in a series A, helping surgeons practice performing surgeries through their VR platform. —Matthew Holt

from The Health Care Blog https://ift.tt/3mUfrJC

It’s complicated. A deep dive into the Viz/Medicare AI reimbursement model.

By LUKE OAKDEN-RAYNER

In the last post I wrote about the recent decision by CMS to reimburse a Viz.AI stroke detection model through Medicare/Medicaid. I briefly explained how this funding model will work, but it is so darn complicated that it deserves a much deeper look.

To get more info, I went to the primary source. Dr Chris Mansi, the co-founder and CEO of Viz.ai, was kind enough to talk to me about the CMS decision. He was also remarkably open and transparent about the process and the implications as they see them, which has helped me clear up a whole bunch of stuff in my mind. High fives all around!

So let’s dig in. This decision might form the basis of AI reimbursement in the future. It is a huge deal, and there are implications.


Uncharted territory

The first thing to understand is that Viz.ai charges a subscription to use their model. The cost is not what was included as “an example” in the CMS documents (25k/yr per hospital), and I have seen some discussion on Twitter that it is more than this per annum, but the actual cost is pretty irrelevant to this discussion.

For the purpose of this piece, I’ll pretend that the cost is the 25k/yr in the CMS document, just for simplicity. It is order-of-magnitude right, and that is what matters.

A subscription is not the only way that AI can be sold (I have seen other companies who charge per use as well) but it is a fairly common approach. Importantly though, it is unusual for a medical technology. Here is what CMS had to say:

As CMS notes here, they don’t have much experience with technology-by-subscription reimbursement. I don’t know for sure if this is the first time they have had to consider this issue, but it might be. Certainly the CMS/Medicare model is to reimburse per service provided, so dealing with subscriptions is outside of their wheelhouse.

It is worth noting that other models are under review. For example, frequent flyer in medical AI news IDx (recipients of the first “autonomous AI” FDA approval) have applied for a fee-for-service payment model under the Outpatient Prospective Payment System (OPPS – pdf link explaining this payment system). This appears to be more like the “pay per procedure” funding model we are used to with mammography CAD (in this case, the proposed rule is for the provider to receive a reimbursement of $11-$34^ for each use of the IDx algorithm).

But regardless, CMS is blazing a new trail with Viz.

Let’s revise what they plan to do:

  • Each year, they will determine the average number of patients who are given an AI-assisted scan per subscription (Viz is selling subscriptions by site, meaning each hospital needs a subscription)
  • They will divide the subscription cost by the number of patients to get the per patient cost
  • They will reimburse at this per patient cost for the next year

As far as mechanisms to deal with a yearly subscription cost on a per patient basis, it sounds fine, at least at first glance.


It’s complicated

As anyone who deals with healthcare as a system would appreciate, it is always much more complicated than it sounds.

An uncomplicated read of the rules might suggest that big hospitals are going to make out like bandits here. $1000 is less than nothing to a hospital, but the scan volumes estimated in the CMS documents are low. CMS estimates that hospitals would use this technology on less than 100 patients per year. Here is the indication for use from the FDA:

“ContaCT is indicated for patients older than 22 years of age. Additionally, the patient should have undergone a stroke protocol assessment after presenting to the Healthcare Facility and receive a head and neck CT angiogram (CTA) during their stroke protocol assessment.”

Indicated patient population, FDA

I asked around, and even mid-sized hospitals are scanning 1500-2000 code-strokes^^ per year. Large stroke centres are doing more than 5000.

Which would, I naively assumed, mean that for an outlay of 25k the hospital will bring home a fresh 5 mil. Tasty.

But… it’s complicated.

It turns out that far fewer patients than this are actually eligible for the reimbursement. Here is some Medicare data supplied by Chris:

So you know how everyone was freaking out that this AI was being reimbursed at $1000 per patient? If you take the total reimbursement and divide it by the number of patients the AI is actually applied to, you get between $30 and $80.

There are multiple exclusion factors, so in this case a large stroke centre might do 6,300 code stroke studies, but only around 4,000 get the scan that ContaCT uses to detect blockages. About half of these patients are covered by Medicare, and only half again go on to inpatient admissions. Then there is the final eligibility step, which drops the number of reimbursable patients from 1,000 to only 142.

CMS rules state that they will only pay a New Technology Add-on Payment (NTAP) if the patient was a loss-maker for the hospital – that is, they cost more to treat than the hospital receives in payments already. Patient payments from Medicare are received as set-value bundles for specific encounter types, called DRGs (diagnosis related groups). You can see the DRG list here (pdf link), an explanation of all things DRG here (pdf as well), and a good summary of the NTAP system here.

CMS Reimbursements by DRG for stroke. I think this might be in the right ballpark, but I could have messed up the formulas.

In general, surgical reimbursements in the US are higher than medical reimbursements, which is important because a thrombectomy is considered surgical rather than medical. A thrombectomy (also called clot retrieval) is when an interventional neuroradiologist (INR) physically removes the clot from the brain, restoring blood flow.

So if everything goes well and ContaCT gets a patient to the INR in time for a thrombectomy, the hospital gets a higher reimbursement, but is less likely to receive the ContaCT NTAP.

This makes the NTAP reimbursement something of a consolation prize. The hospital will get the extra $1000, but because of longer hospitalisations and worse outcomes without thrombectomy, the shortfall is often more than the NTAP will cover*. As a general rule, this will be more important at spoke hospitals (small referrer centres) who will have a higher proportion of loss-making patients, whereas at large stroke centres they will typically get higher reimbursements as the referred patients undergo more thrombectomies, but will receive fewer NTAPs. In Chris’ figures above, the spoke hospital could receive around half as much NTAP reimbursement as the hub, despite scanning 6 times fewer patients.

So, the amount of reimbursement is likely much lower than the naive read suggested, but this doesn’t make the NTAP a bad thing. No hospital admin will turn down extra cash.

But it does mean that the main selling point isn’t the reimbursement, particularly at the hub hospitals. It is the chance to get more patients to thrombectomy that is the real value-maker.


Generating value

All of this is from Chris (the Viz CEO), so take with as big a grain of salt as you would like, but one number really jumped out at me during our talk: at large stroke hubs with ContaCT in use, thrombectomy rates have increased by 50-60%**.

This means that patients are truly being retrieved quicker, receiving better treatment, and in turn hospitals are getting larger reimbursements for their care. They are thus more likely to cover costs or even make a profit on these patients, unrelated to the NTAP. I only have a rough sense of how this might play out, but the difference to the hospital bottom-line could be much larger than the estimated $150,000 in NTAP payments.

I’ve written many times about the struggle to generate value for AI vendors, but it seems like Viz isn’t facing this problem at all, which is shown in the other number that Chris told me: ContaCT, without the NTAP, is already deployed in 500 hospitals across the US!


What could go wrong?

So Viz will do ok out of this, but ContaCT has some pretty unique attributes. What about the funding model broadly? Does it make sense to use NTAP reimbursement to pay for subscription services? Will it incentivise both the use of good technology, and the development of useful AI models?

The US payment system is so complicated that there can be no universal interpretation or guidance, since the NTAP system relies on DRGs, loss-making, and yearly estimations of unit costs to determine reimbursement value. But as a broad simplification, we can see a few things:

  • This is a funding model that rewards volume of use, rather than value to patient. I’m not a health economist, but this issue has been hotly debated for many years. In this case, there is pretty good evidence that saving time saves money (estimated at $1059 per minute of delay to thrombectomy), but the broader point remains.

There is another possible problem though.

https://platform.twitter.com/widgets.js

  • Reimbursements are determined by estimates of volume per subscription. Thus, reimbursements will be higher at hubs than spokes, despite the same subscription cost. Furthermore reimbursements may come down as volumes increase (as more large providers deploy the system).
  • If reimbursements fall, smaller providers with low volumes may be unable to recoup costs.
  • Developers will have the choice to
    • maintain subscription costs, resulting in falling reimbursement to cost ratios for healthcare providers. This is likely to result in fewer subscriptions.
    • reduce subscription costs to incentivise use by smaller providers.
    • do the usual subscription service tomfoolery like having “premium” and “basic” subscription tiers which allow for smaller providers to get cheaper access, but are essentially just “pay-per-use” contracts by stealth.

The combination of the first two points is not particularly promising for the funding model as each leads to falling revenue for the developers. As Elliot says above, this could be the start of a race to the bottom***.

On the flip side, it is a clear mechanism to generate revenue for AI startups, which has been a serious challenge for most.

But it may also be, as appears to be the case with Viz, that CMS NTAP approval is less a mechanism by which startups achieve viability and more an endorsement of AI startups that were already viable in the first place. Time will tell.


^ Part of what makes the Viz finding model hard to wrap your head around is the difference in reimbursements. IDx gets up to 30 bucks, Viz gets 1000! It isn’t as weird as it sounds though.

^^ A “code stroke” is a rapid response protocol for suspected stroke, and usually includes an unenhanced CT brain, a carotid/COW CT angiogram, and a CT perfusion study where this is available. This sort of study is what ContaCT is approved for by the FDA.

* Worth noting here that the loss is unrelated to ContaCT, and was going to happen anyway. The $1000 is extra money the hospital wouldn’t have, which offsets the loss at least a little. Also worth noting that as the figures from Chris showed, the reimbursement of patients is often below $1000, as it covers up to 65% of the loss the hospital makes on the patient, to a maximum of $1000.

** This is a really interesting element of the story. Do we need to train 50% more interventional neuroradiologists? AI creates jobs!

*** This is unlikely to be a problem with Viz, where the particular interplay of DRGs and reimbursements provides payments to spoke centres at a relatively higher rate, supporting the small providers to continue their subscriptions. It could be a serious issue for other AI vendors if the funding model is used more widely.

Luke Oakden-Rayner is a radiologist in South Australia, undertaking a Ph.D in Medicine with the School of Public Health at the University of Adelaide. This post originally appeared on his blog here.

from The Health Care Blog https://ift.tt/305dAYQ

THCB Gang Episode 26 LIVE 9/24 from 1PM PT/4PM ET!

Episode 26 of “The THCB Gang” will be live-streamed on Thursday, September 24th! Tune in below!

Joining Matthew Holt (@boltyboy) are some of our regulars: health futurist Ian Morrison (@seccurve), MD turned leadership coach Maggi Cary (@MargaretCaryMD), health care consultant Daniel O’Neill (@dp_oneill), and patient safety expert Michael Millenson (@MLMillenson). The conversation will focus on the ACA hanging by a thread as well as other policy changes surrounding health care.

If you’d rather listen to the episode, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels — Zoya Khan

from The Health Care Blog https://ift.tt/2S72lLf